莫西沙星与左氧氟沙星治疗社区获得性肺炎的随机对照研究被引量：15

Randomized controlled clinical trial of moxifloxacin versus levofloxacin in the treatment of community acquired pneumonia

下载PDF

导出

摘要目的评价莫西沙星注射液与左氧氟沙星注射液在治疗社区获得性肺炎中的临床疗效和安全性。方法采用区组随机、开放、阳性药物对照的研究方法。结果治疗结束后d7,PP分析:试验组和对照组的临床有效率分别为97.0%和92.1%;细菌清除率:PP/MBE分析两组分别为96.0%和96.7%。安全性分析:试验组和对照组的不良反应发生率均为20%。上述结果经统计学检验两组比较均无显著性差异(P>0.05)。结论莫西沙星注射液和左氧氟沙星注射液治疗社区获得性肺炎安全、有效。 Objective To evaluate the efficacy and safety of moxifloxacin for the treatment of the patients with community acquired pneumonia. Methods A randomized controlled, parallel, block, open clinical trial was conducted. Patients were randomly divided into groups. Results The overall efficacy rates in PP were 97.0% and 92.1% , respectively. The bacterial eradication rates of each group in PP/MBE were 96.0% and 96.7% , respectively. The adverse drug reaction rates, which related to study drug of each group were 20%. The results showed that there were no statistical differences between these two groups （ P 〉 0.05 ）. Conclusion Moxifloxacin was effective and safe as levofloxacin in the treatment of community acquired pneumonia.

作者杨惠芬刘德梦朱宁王哲宋诗铎胡文芝

机构地区天津医科大学第二医院感染科

出处《中国抗生素杂志》 CAS CSCD 北大核心 2009年第11期703-704,I0001,I0002,共4页 Chinese Journal of Antibiotics

关键词莫西沙星左氧氟沙星社区获得性肺炎随机对照研究 Moxifloxacin Levofloxacin Community acquired pneumonia Randomized controlled trials

分类号 R978.19 [医药卫生—药品]

引文网络
相关文献

参考文献7

1Balfour J A B,Wiseman L R.Moxifloxacin[].Drugs.1999
2Lopez H,Vilches V,Scarano S,et al.Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens[].International Journal of Antimicrobial Agents.2001
3A Speciale,R Musumeci,G Blandino,I Milazzo,F Caccamo,G Nicoletti.Minimal inhibitory concentration and time-kill determination of moxifloxacin against aerobic and anaerobic isolates[].International Journal of Antimicrobial Agents.2002
4Breilh D,Jougon J,Djabarouti S,et al.Diffusion of oral andintravenous 400mg once-daily moxifloxacin into lung tissue:apharmcokinetic steady-state[].Journal of Chemotherapy.2003
5Krasemann C,,Meyer J.Tillotson G Evaluation of the clinical microbiology profile of moxifloxacin[].Clinical Infectious Diseases.2001
6Torres A,Muir JF,Corris P,et al.Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquire pneumonia[].European Respiratory Journal.2003
7Starakis I,Gogos CA,Bassaris H.Five-day moxifloxacin th-erapy compared with-7day co-amoxiclav therapy for thetreatment of acute exacerbation of chronic bronchitis[].Int JAntimicrob Agents.2004